Figure 6

Figure 6

Heteronemin suppressed the tube formation, migration and phosphorylation of VEGF-C/VEGFR-3/LYVE-1 in human lymphatic endothelial cells. (A) Cells were treated with the indicated concentrations of heteronemin (indicated as SP-1). The capillary-like structure formation was examined by tube formation (scale bar = 500 μm; 20× magnification). (B) The quantification of tube formation was performed using Image-J to validate the anti-lymphangiogenic property of SP-1. (C) LECs were treated with SP-1. Then, the expression of LYVE-1and PROX-1 was determined by Western blot analysis. (D) The quantitative densitometry of the relative levels of LYVE-1 and PROX-1 was measured by Image-Pro Plus. Data are expressed as the mean ± SEM of at least three independent experiments. * p < 0.05; ^#p < 0.01 compared with the control group.